- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
| Fr | RedChip Companies, Inc.: Avalon Advanced Materials and Virax Biolabs Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 326 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / May 15, 2026 / RedChip Companies will air interviews with Avalon Advanced Materials Inc. (OTCQB:AVLNF)(TSX:AVL) and Virax Biolabs Group Limited (Nasdaq:VRAX) on the RedChip... ► Artikel lesen | |
| 11.05. | Virax Mulls Bringing UK Biotech Startup's Immune Profiling Platform to China, Chair Says | 1 | Yicai Global | ||
| 10.04. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 31.03. | Virax Biolabs-Tochter erhält ISO-Qualitätszertifizierungen | 1 | Investing.com Deutsch | ||
| 31.03. | Virax BioLabs Group Limited: Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation | 127 | PR Newswire | LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its... ► Artikel lesen | |
| 30.01. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.01. | H.C. Wainwright senkt Kursziel für Virax Biolabs auf 1 US-Dollar | 2 | Investing.com Deutsch | ||
| 12.01. | Virax Biolabs stock price target lowered to $1 at H.C. Wainwright | 1 | Investing.com | ||
| 04.12.25 | Virax Biolabs Unveils $5 Million Private Placement | 4 | RTTNews | ||
| 04.12.25 | Virax Biolabs (VRAX) Stock Cools After Hours Following 75% Rally | 1 | Benzinga.com | ||
| 02.12.25 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.11.25 | Virax BioLabs Group Limited: Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes | 295 | PR Newswire | LONDON, Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection... ► Artikel lesen | |
| 26.08.25 | Virax BioLabs Group Limited: Virax Biolabs Partners with Emory University on ViraxImmune Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September | 300 | PR Newswire | LONDON, Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune... ► Artikel lesen | |
| 18.07.25 | Virax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency | 326 | PR Newswire | LONDON, July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 75,40 | -4,25 % | BERENBERG stuft Biontech auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Biontech von 155 auf 140 US-Dollar gesenkt, aber die Einstufung auf "Buy" belassen. Mit dem neuen Kursziel trage er dem zunehmenden... ► Artikel lesen | |
| EVOTEC | 4,696 | -0,09 % | KURSRUTSCH bei Nel ASA und Evotec! KURSCHANCE bei HPQ Silicon! | Steht die Aktie von HPQ Silicon vor einer Neubewertung? Dafür gibt es jedenfalls gute Gründe. Die Hochleistungsbatterien haben erneut überzeugt. Damit könnte für Anwendungen in Drohnen, Verteidigung... ► Artikel lesen | |
| MODERNA | 41,525 | -1,65 % | JEFFERIES stuft Moderna auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Moderna auf "Hold" mit einem Kursziel von 45 US-Dollar belassen. Andrew Tsai bezog am Dienstag Stellung zur jüngsten Kursstärke... ► Artikel lesen | |
| BIOGEN | 164,58 | -0,87 % | Biogen Inc.: Biogen Completes Acquisition of Apellis Pharmaceuticals | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis... ► Artikel lesen | |
| ILLUMINA | 123,12 | +0,36 % | RBC Capital assumes Illumina stock coverage with outperform rating | ||
| CRISPR THERAPEUTICS | 42,250 | +1,39 % | 1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? | ||
| VIKING THERAPEUTICS | 24,950 | -4,41 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| ATAIBECKLEY | 3,680 | +6,36 % | Trump zündet den Turbo: Warum AtaiBeckley und Emyria jetzt im Fokus der Anleger stehen | ||
| ASEP MEDICAL | 0,100 | -100,00 % | CSE Bulletin: Suspensions - VSBLTY Groupe Technologies Corp., NuRAN Wireless Inc., GOAT Industries Ltd., BYT Holdings Ltd., ASEP Medical Holdings Inc., BioVaxys Technology Corp. | Le 6 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,660 | +0,79 % | Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo... ► Artikel lesen | |
| TWIST BIOSCIENCE | 42,900 | +1,35 % | Cathie Wood's ARK sells Twist Bioscience, buys Natera stock | ||
| OCULAR THERAPEUTIX | 7,500 | -5,06 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| AGIOS | 24,200 | 0,00 % | Agios Pharmaceuticals, Inc.: Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease | sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,962 | -2,43 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| GENPREX | 0,827 | -0,37 % | Genprex collaborators present diabetes gene therapy data |
Das Unternehmen VIRAX BIOLABS GROUP LIMITED kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,324 (+211,21 %) liegt der Kurs bei 0,478 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIRAX BIOLABS GROUP LIMITED finden Sie auf Wallstreet Online.